Abstract: Various methods are described that provide for high resolution melt (HRM) genotyping. Some embodiments comprise providing a locus specific primer, and two allele specific primers each comprising at least one single nucleotide polymorphism (SNP) allele-hybridizable sequence, wherein at least one of the allele specific primers also comprises at least one nucleotide alteration. In some embodiments, a nucleic acid is provided comprising a SNP base located within 1-20 bases of its 3? end. Some embodiments comprise hybridizing the locus specific primer and at least one of the allele specific primers to the nucleic acid, amplifying the hybridized nucleic acid using pyrophosphorolysis activated polymerization (PAP) PCR, and determining the melting temperature (Tm) of the resulting amplicons, for example, using HRM. In some embodiments, reaction mixtures and kits for HRM genotyping are provided.

Abstract: Compositions and methods for the identification of agents useful for the treatment of neurological disorders, including schizophrenia, are provided.

Abstract: Methods and kits for assessing severity index for alcohol abuse, drug abuse, and other reward deficiency syndromes. It has been discovered that a multifaceted non-specific RDS behaviors should be considered as the true “reward” phenotype (endophenotype) instead of a single subset RDS behavior such as alcoholism. In an embodiment of the present invention, it has been discovered that there are at least eleven risk alleles associated with ten candidate genes. The methods and kits of the present invention satisfy the need to classify patients at genetic risk for drug/alcohol seeking behavior prior to or upon entry to residential and or non-residential chemical dependency and pain programs.

Abstract: The present invention provides biomarkers for the diagnosis and prognosis of endometriosis. Generally, the methods of this invention find use in diagnosing or for providing a prognosis for endometriosis by detecting the expression levels of biomarkers, which are differentially expressed (up- or down-regulated) in endometrial cells from a patient with endometriosis. Similarly, these markers can be used to diagnose reduced fertility in a patient with endometriosis or to provide a prognosis for a fertility trial in a patient suffering from endometriosis. The present invention also provides methods of identifying a compound for treating or preventing endometriosis. Finally, the present invention provides kits for the diagnosis or prognosis of endometriosis.

Abstract: Provided are methods and kits for predicting the prognosis of a subject diagnosed with multiple sclerosis by determining the expression level of polynucleotides which are differentially expressed between subjects diagnosed with multiple sclerosis and having good or poor clinical outcome. Also provided are methods and kits for selecting a treatment regimen of a subject diagnosed with multiple sclerosis.

Abstract: Described herein is a treatment comprising the following step: (a) injecting a therapeutically effective amount of a pharmaceutical composition into the celiac artery of an individual, wherein the pharmaceutical composition reverses recent onset Type 1 Diabetes (T1D). Also described is a method for identifying an individual who will be responsive to this treatment. In addition there is described a device containing the pharmaceutical composition for injecting the pharmaceutical composition into the celiac artery.

Abstract: Disclosed herein, in certain instances, are methods, systems and kits for the diagnosis, prognosis and determination of cancer progression of a cancer in a subject. Further disclosed herein, in certain instances, are methods, systems and kits for determining the treatment modality of a cancer in a subject. The methods, systems and kits comprise expression-based analysis of biomarkers. Further disclosed herein, in certain instances, are probe sets for use in assessing a cancer status in a subject. Further disclosed herein are classifiers for analyzing a cancer.

Abstract: Methods for creating a selector of mutated genomic regions and for using the selector set to analyze genetic alterations in a cell-free nucleic acid sample are provided. The methods can be used to measure tumor-derived nucleic acids in a blood sample from a subject and thus to monitor the progression of disease in the subject. The methods can also be used for cancer screening, cancer diagnosis, cancer prognosis, and cancer therapy designation.

Abstract: Provided herein are methods and compositions for identifying subjects, including canine subjects, as having an elevated risk of developing cancer or having an undiagnosed cancer. These subjects are identified based on the presence of germ-line risk markers.

Abstract: The disclosure features a method of treating cancer by lowering a patient's two gene score (TGS), particularly by increasing the number of tumor-infiltrating leukocytes. In addition, a TGS animal model and uses thereof are provided.

Abstract: The present invention relates to a method for the prognosis of bone metastasis in renal cell carcinoma which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF gene expression level, amplification or translocation. The invention also relates to a method for predicting early bone metastasis in a subject suffering renal cell carcinoma. The invention also relates to a c-MAF inhibitor as therapeutic agent for use in the treatment of renal cell carcinoma metastasis. The invention relates to kits for predicting bone metastasis and predicting the clinical outcome of a subject suffering from bone metastasis. Finally, the invention relates to a method for typing of a subject suffering renal cell carcinoma and for classifying a subject from renal cell carcinoma into a cohort.

Abstract: The present invention relates to a method for the prognosis of bone metastasis in cancer which comprises using a probe to determine if a gene of interest is amplified in a primary tumor sample. Likewise, the invention also relates to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise using a probe to determine the expression level of a gene of interest, or the amplification or translocation of a gene of interest. The invention also relates to a method for predicting early bone metastasis in a subject suffering cancer. The invention also relates to a c-MAF inhibitor as therapeutic agent for use in the treatment of cancer metastasis. The invention relates to kits for predicting bone metastasis and predicting the clinical outcome of a subject suffering from bone metastasis. Finally, the invention relates to a method for typing of a subject suffering cancer and for classifying a subject from cancer into a cohort.

Abstract: Methods of treatment, diagnosis, and determining prognosis of subjects with cancer, generally comprising determining levels of glycine metabolism or a mitochondrial 1-carbon (1-C) pathway enzyme, e.g., SHMT2, MTHFD1L, or MTHFD2, and optionally administering an antifolate or an agent that inhibits a mitochondrial 1-carbon (1-C) pathway enzyme, e.g., SHMT2 or MTHFD2.

Abstract: The invention provides methods of detecting cancer biomarkers, such as one or more SWI/SNF complex mutations, in order to determine a cancer subject's amenability to therapeutic treatment with a BRM inhibitor. Kits, methods of screening for candidate BRM inhibitors, and associated methods of treatment are also provided.

Abstract: The present invention provides methods for selecting a suitable anticancer drug for the treatment of patient with non-small cell lung cancer (NSCLC). The present invention also provides methods for determining drug resistance in NSCLC patients receiving EGFR inhibitor therapy.

Abstract: Disclosed herein, are methods, systems, compositions, arrays, and kits for using biomarkers, biomarker genes (e.g. EP300, MLL2, BCL-2, RB1, LRP1B, PIM1, TSC2, TNFRSF11A, SMAD4, PAX5, CARD11, ACTG2, LOR, GAPT, CCND2, SELL, GEN1, HDAC9, CD79B, MYD88, and ROS1) or biomarker gene expression levels for stratifying a patient having a hematological malignancy such as DLBCL for treatment, and administering a TEC inhibitor to selected patients. Also disclosed herein are methods, systems, compositions, arrays, and kits for using biomarkers, biomarker genes, or biomarker gene expression levels for monitoring a patient during treatment of a hematological malignancy such as DLBCL or FL or for optimizing a treatment regimen with a TEC inhibitor.

Abstract: A method for detection, visualization and/or comparison of polynucleotide sequences of interest using specially designed sets of long and short probes that enhance resolution and simplify visualization and detection. Probe compositions useful for practicing this method and procedures for identifying useful probes and probe combinations. These methods are useful for the detection of genomic rearrangements, especially those associated with various diseases, disorders and conditions including cancer or for assessment of genomic rearrangements associated with therapy. The probe compositions may be used in kits for detection of genetic rearrangements or in companion diagnostic products or kits, such as kits for the diagnosis or assessment of predisposition to cancer such as colorectal cancer.

Abstract: The present invention provides a method for detecting mutations in the PALB2 gene in pancreatic cancer patients and in individuals having a family history of pancreatic cancer. Methods are also provided for diagnosing a predisposition to pancreatic cancer, for predicting a patient's response to pancreatic cancer therapies, and for treating pancreatic cancer, based on presence of a PALB2 mutation or abberant PALB2 gene expression in a patient.

Abstract: The application provides methods of prognosing and classifying lung cancer patients into poor survival groups or good survival groups and for determining the benefit of adjuvant chemotherapy by way of a multigene signature. The application also includes kits and computer products for use in the methods of the application.

Abstract: A polynucleotide comprising at least the final six nucleotides of one of the following primer sequences, or a sequence complementary thereto: SEQ. ID NOS. 3 to 16, 18, 20 to 33, 35 or 37 to 39. A method of detecting the presence or absence of a mutation in the PIK3CA gene, wherein the mutation is one of H1047R, H1047L, E542K and E545K, and preferably ARMS primers are combined with Scorpion primers.

Abstract: Various methods and compositions are provided for identifying and/or selecting soybean plants or soybean germplasm with improved resistance to Frogeye Leaf Spot and/or Brown Stem Rot. In certain embodiments, the method comprises detecting at least one marker locus that is associated with resistance to Frogeye Leaf Spot and/or Brown Stem Rot. In other embodiments, the method further comprises detecting at least one marker profile or haplotype associated with resistance to Frogeye Leaf Spot and/or Brown Stem Rot. In further embodiments, the method comprises crossing a selected soybean plant with a second soybean plant. Further provided are markers, primers, probes and kits useful for identifying and/or selecting soybean plants or soybean germplasm with improved resistance to Frogeye Leaf Spot and/or Brown Stem Rot.

Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. Vaccines and diagnostic assays are also contemplated herein.

Abstract: Processes and compositions are provided for the detection of hepatitis viruses in a sample. Particular processes and compositions are provided for the selective detection of HDV. Also provided are processes and compositions for the simultaneous detection of two or more hepatitis viruses that for the first time provide rapid, reliable, and simple detection of any known hepatitis vims in a sample using a single set of reaction conditions.

Abstract: Disclosed are nucleic acid oligomers, including amplification oligomers, capture probes, and detection probes, for detection of Hepatitis E Virus (HEV) nucleic acid. Also disclosed are methods of specific nucleic acid amplification and detection using the disclosed oligomers, as well as corresponding reaction mixtures and kits.

Abstract: The invention relates to a nanoproduct useful in prophylaxis and medicine, both human and veterinary as well as to a medical use of the same. The invention discloses Lactobacillus reuteri DAN080 strain with deposit number DSM 15693 for use in medicine. The various forms of preparations comprising the Lactobacillus reuteri DAN080 strain with deposit number DSM 15693 are disclosed for use in medicine as therapeutic and prophylactic agent, especially as an antimicrobial agent, in prophylaxis and treatment of medical condition conditions developing as a result of infections caused by bacteria, fungi, and other pathogens of the gastrointestinal tract, body surface, and other systems, such as urogenital system, respiratory system, in vertebrates or as a therapeutic and/or prophylactic agent for the treatment and prevention of development of gout (podagra) and/or for increasing the activity of lysozyme in an organism of vertebrate, especially human, other mammal or bird.

Abstract: Provided are methods and compositions using activated carbon for optimizing purification and clarification of sugar streams produced from cellulosic or lignocellulosic biomass. Also provided are methods and compositions for decreasing one or more undesirable products during pretreatment.

Abstract: A method for manufacturing a metal structure (130) for use in a downhole assembly comprises plastically deforming at least a portion of the metal structure (130); and heating at least the deformed portion of the metal structure to a temperature below its critical and/or transformation temperature. An assembly for performing the method comprises a production fixture (370) configured to receive the metal structure (130), wherein the production fixture is adapted to undergo heating to a temperature below and/or up to the critical and/or transformation temperature of the metal structure. By heating at least the deformed portion of the metal structure to a temperature below its critical and/or transformation temperature, the metal structure may undergo stress relief, which may help prevent undesirable movement of deformed portion, e.g. collet fingers of a catching apparatus, against the direction of deformation after impact(s) and/or shock(s) from moving objects, in use.

Abstract: A method of manufacturing an airfoil includes the steps of depositing multiple layers of powdered metal onto one another. The layers are joined to one another with reference to CAD data relating to a particular cross-section of an airfoil. The airfoil is produced with leading and trailing edges joined by spaced apart pressure and suction sides to provide an exterior airfoil surface. An exterior wall provides the exterior airfoil surface at the leading edge. An impingement wall is integrally formed with the exterior wall to provide an impingement cavity between the exterior wall and the impingement wall. Multiple impingement holes are provided in the impingement wall. The impingement holes are spaced laterally across the impingement wall.

Abstract: A method of manufacturing yield ratio-controlled steel, including the steps of subjecting alloy steel to rolling or wire drawing, thus obtaining a bar material; performing a first heat treatment, in which the material is heated and maintained for a predetermined period of time at a first temperature ranging from Ac1 to Ac3 based on Ac1 and Ac3 transformation temperatures; and cooling the material to a second temperature ranging from Mf to Ms based on a martensite start temperature (Ms) and a martensite finish temperature (Mf), and performing a second heat treatment, in which the material is maintained at the second temperature for a predetermined period of time.

Abstract: Disclosed is a method for producing steel for blades having a metal composition consisting of, by mass, 0.55% to 0.8% C, not more than 1.0% Si, not more than 1.0% Mn, 12.0% to 14.0% Cr, not more than 1.0% Mo, not more than 1.0% Ni, and the balance Fe with impurities, comprising: a batch annealing step for batch annealing a material to be cold rolled having the metal composition at a temperature of 500° C. to 700° C. for 3 to 30 hours; a continuous annealing step for continuously annealing the batch annealed material for 5 to 30 minutes so that the batch annealed material is heated to at least an Ac1 transformation point of the metal composition step to obtain a continuously annealed material; and a cold rolling step for cold rolling the continuously annealed material, wherein the continuous annealing step and the cold rolling step are performed at least once, respectively.

Abstract: The present invention relates to a process for the selective recovery of the rare earth metals from an acidic aqueous sulfate solution comprising phosphates, aluminum and heavy rare earth metals, and possibly medium rare earth metals, iron(II) and titanium, characterized in that it comprises the following successive stages: a) neutralization at a pH of between 3 and 4 of an acidic aqueous sulfate solution comprising phosphates, aluminum and heavy rare earth metals, and possibly medium rare earth metals, iron(II) and titanium, the solution having a molar ratio Al/P>1 and a concentration of sulfates>100 g/l, by addition of a base, so as to precipitate the phosphate and the aluminum and the possible titanium, b) liquid/solid separation between the precipitate formed by the phosphate and the aluminum and the possible titanium and the aqueous sulfate solution, c) recovery of the aqueous sulfate solution, d) addition of phosphates to the aqueous sulfate solution obtained in stage c) such that the molar ratio

Abstract: Methods described herein generally relate to the treatment of carbonaceous materials with ozone to facilitate the subsequent recovery of metal species (e.g., precious metals) from the carbonaceous material. In some cases, the method may involve exposure of a carbonaceous material to a relatively low amount of ozone. In some cases, the carbonaceous material may be subjected to oxidizing conditions, e.g. by autoclaving or bio-oxidation, prior to ozone treatment. Such embodiments may allow for more simplified and cost-effective methods for metal recovery.

Abstract: There are provided processes for treating fly ash. For example, the processes can comprise leaching fly ash with HCl so as to obtain a leachate comprising aluminum ions and a solid, and separating the solid from the leachate; reacting the leachate with HCl so as to obtain a liquid and a precipitate comprising the aluminum ions in the form of AlCl3, and separating the precipitate from the liquid; and heating the precipitate under conditions effective for converting AlCl3 into Al2O3 and optionally recovering gaseous HCl so-produced.

Abstract: Disclosed herein are processes for selectively solubilizing iron from a substrate material containing both titanium and iron, such as ilmenite ore. In one embodiment, the process comprises contacting a substrate material comprising iron and titanium with an aqueous solution of an extractant selected from the group consisting of malonic acid, a malonic acid salt, citric acid, a citric acid salt, and mixtures thereof, at a temperature between about 25° C. and about 160° C. for a time sufficient to form an aqueous leachate comprising iron and titanium, and solids comprising titanium; wherein the leachate has a titanium content of 25 weight percent or less, based on the sum of the iron and the titanium contents of the leachate on a weight basis.

Abstract: The present invention relates to a method for producing rare-earth metals (REM) compounds by complex processing of apatite, in particularly to a method for concentrating rare-earth metals (REM) in phosphogypsum, where to a process of decomposition of the REM containing raw phosphate material with sulphuric acid, a sodium salt in the amount of 0.25-5.0 kg in terms of Na2O or a potassium salts in the amount of 0.25-5.0 kg in terms of K2O or a mixture thereof in the amount of 0.25-5 kg in terms of Na2O and K2O to 1 kg of REM (in terms of Ln2O3 present in raw phosphate material) is added. The yield of REM transfer into phosphogypsum is up to 98%.

Abstract: A silver electrode joint having a high joint strength obtained by actively minimizing the particle size of a silver-zinc intermetallic compound at the solidification point. A joint obtained by joining an article to be joined, the joint including silver at least as the surface layer thereof, using a solder alloy which comprises 2-9 wt % of zinc, 0.0001-0.1 wt % of manganese and the balance consisting of tin, the solder joint having a joint interface wherein the particle size of a silver-zinc intermetallic compound, which is formed by silver being the surface layer of the article to be joined and zinc in the solder alloy, is 5 ?m or less.

Abstract: A nickel-based alloy, consisting of (in mass %) 1.5-3.0% Si, 1.5-3.0% Al, and >0.1-3.0% Cr, where Al+Si+Cr is ?4.0 and ?8.0 for the contents of Si, Al, and Cr in %; 0.005-0.20% Fe, 0.01-0.20% Y, and <0.001-0.20% of one or more the elements Hf, Zr, La, Ce, Ti, where Y+0.5*Hf+Zr+1.8*Ti 0.6*(La+Ce) is ?0.02 and ?0.30 for the contents of Y, Hf, Zr, La, Ce, and Ti in %; 0.001-0.10% C; 0.0005-0.10% N; 0.001-0.20% Mn; 0.0001-0.08% Mg; 0.0001-0.010% O; max. 0.015% S; max. 0.80% Cu; Ni remainder; and the usual production-related impurities.

Abstract: A nickel alloy includes a proportion by weight of Cr of 12.3% to 13.7%, a proportion by weight of Al of 4.3% to 4.7% and a proportion by weight of Co of 4% to 6%. The components are preferably Cr, Mo, Re and/or W, Al, Ti, Ta, Hf, Si, reactive elements including actinides and lanthanides, C, optionally the components Zr and/or B. The proportions by weight are selected such that both a desired high creep resistance and also a desired high hot corrosion resistance are achieved. A turbine blade is made of the nickel alloy.

Abstract: The present invention relates to a method for manufacturing a high purity Mn, the method comprising: placing a Mn raw material in a magnesia crucible to perform melting with the use of a vacuum induction melting furnace (VIM furnace) at a melting temperature of 1240 to 1400° C. under an inert atmosphere of 500 Torr or less; then adding calcium in a range between 0.5 and 2.0% of the weight of Mn to perform deoxidation and desulfurization; casting the resultant in an iron mold after the completion of the deoxidation and desulfurization to manufacture an ingot; then placing the Mn ingot in a skull melting furnace; reducing pressure to 10?5 Torr or less with a vacuum pump; starting heating and keeping the Mn in a molten state for 10 to 60 minutes; and then ending the melting reaction for obtaining a high purity metal Mn. Provided is a method for manufacturing a high purity metal Mn from a commercially available electrolytic Mn.

Abstract: A magnesium alloy including about 2 percent by weight to about 8 percent by weight zinc, about 0.1 percent by weight to about 3 percent by weight manganese, about 1 percent by weight to about 6 percent by weight tin, about 0.1 percent by weight to about 4 percent by weight yttrium, and magnesium.

Abstract: A homogenous brazing material essentially consisting of relatively low amounts of silver and nickel together with copper, zinc, and other constituents is provided. The brazing material has a working temperature exceeding 630° F. and is preferably between about 1250° F. and 1500° F. The brazing material preferably has about 30 percent by weight of silver, about 36 percent by weight of copper, about 32 percent by weight of zinc, and about 2 percent by weight of nickel. The addition of nickel in the above-specified amount improves resistance against interface corrosion in aqueous solutions, aids in the strength of the alloy, and provides improved wettability on ferrous and non-ferrous substrates. The brazing material may also include a flux, such as a core or a coating.

Abstract: A method for forming an austempered iron composition with a nanoscale microstructure includes a step of heating an iron-carbon-silicon alloy with silicon to a first temperature that is lower than A1 for the iron-carbon-silicon alloy. The iron-carbon-silicon alloy is then adiabatically deformed such that the temperature of the iron-carbon-silicon alloy rises to a second temperature which is sufficient to form proeutectoid ferrite and austenite. The iron-carbon-silicon alloy is cooled to a first austempering temperature. The iron-carbon-silicon alloy is then heated to a second austempering temperature that is greater than the first austempering temperature to form a dual phase microstructure. Characteristically, the dual phase microstructure includes proeutectoid ferrite and ausferrite.

Abstract: A steel sheet for nitriding has excellent formability and punchability. The steel sheet has a composition including, in percent by mass, 0.02% to 0.08% of C, 0.1% or less of Si, 0.2% to 1.8% of Mn, 0.05% or less of P, 0.02% or less of S, 0.01% to 0.06% of Al, 0.5% to 1.5% of Cr, 0.01% or less of N, and the balance being Fe and incidental impurities; and has a microstructure including ferrite as a main phase and pearlite and/or bainite as a secondary phase. The ferrite has a fraction of 70% or more in the entire microstructure and an average grain diameter of 5 to 25 gm. An average length of the major axis of cementite present in the secondary phase in a cross section in the rolling direction of the steel sheet is 3.0 ?m or less.

Abstract: A high-performance low-alloy wear-resistant steel sheet and a method of manufacturing the same, which has the chemical compositions (wt %): C: 0.21-0.32%; Si: 0.10-0.50%; Mn: 0.60-1.60%; B: 0.0005-0.0040%; Cr: less than or equal to 1.50%; Mo: less than or equal to 0.80%; Ni: less than or equal to 1.50%; Nb: less than or equal to 0.080%; V: less than or equal to 0.080%; Ti: less than or equal to 0.060%; Al: 0.010-0.080%, Ca: 0.0010-0.0080%, N: less than or equal to 0.0080%, O: less than or equal to 0.0080%, H: less than or equal to 0.0004%, P: less than or equal to 0.015%, S: less than or equal to 0.010%, and (Cr/5+Mn/6+50B): more than or equal to 0.20% and less than or equal to 0.55%; (Mo/3+Ni/5+2Nb): more than or equal to 0.02% and less than or equal to 0.45%; (Al+Ti): more than or equal to 0.01% and less than or equal to 0.13%, the remainders being Fe and unavoidable impurities.

Abstract: Disclosed is an austenitic stainless steel alloy that includes, by weight, about 22% to about 28% chromium, about 3.5% to about 6.5% nickel, about 1% to about 6% manganese, about 0.5% to about 2.5% silicon, about 0.3% to about 0.6% carbon, about 0.2% to about 0.8% niobium, about 0.2% to about 0.8% nitrogen, and a balance of iron. Molybdenum and tungsten are excluded. The alloy is suitable for use in turbocharger turbine housing applications for temperature up to about 980° C.

Abstract: This heat-resistant austenitic stainless steel sheet contains, in mass %, C: 0.05 to 0.15%, Si: 1.0 to 3.5%, Mn: 0.5 to 2.0%, P: not more than 0.04%, S: not more than 0.01%, Cr: 23.0 to 26.0%, Ni: 10.0 to 15.0%, Mo: 0.50 to 1.20%, Ti: not more than 0.1%, Al: 0.01 to 0.10% and N: 0.10 to 0.30%, wherein the total amount of C and N (C+N) is from 0.25 to 0.35%, and the balance is composed of Fe and unavoidable impurities. The heat-resistant austenitic stainless steel can be used in a high-temperature environment that reaches a maximum temperature of 1,100° C.

Abstract: The disclosure is directed to Zr and Hf bearing alloys that are capable of forming a metallic glass, and more particularly metallic glass rods with diameters at least 1 mm and as large as 5 mm or larger. The disclosure is further directed to Zr and Hf bearing alloys that demonstrate a favorable combination of glass forming ability, strength, toughness, bending ductility, and/or corrosion resistance.

Abstract: A process for making a finished or semi-finished article of silver alloy, said process comprising the steps of providing a silver alloy containing silver in an amount of at least 77 wt %, copper and an amount of germanium that is preferably at least 0.5 wt % and is effective to reduce tarnishing and/or firestain, making or processing the finished or semi-finished article of the alloy by heating at least to an annealing temperature, gradually cooling the article; and reheating the article to effect precipitation hardening thereof. The avoidance of quenching reduces the risk of damage to the article.

Abstract: A nanostractured titanium alloy article is provided. The nanostractured alloy includes a developed titanium structure having at least 80% of grains of a grain size?1.0 microns.

Abstract: A high-strength plated steel plate for a welded structural member having a steel composition containing from 0.050 to 0.150% of C, from 0.001 to 1.00% of Si, from 1.00 to 2.50% of Mn, from 0.005 to 0.050% of P, from 0.001 to 0.020% of S, and from 0.005 to 0.100% of Al, having a steel base material having a metal structure containing a ferrite phase and a second phase containing mainly martensite having an average crystal grain diameter of 8 mm or less, and having a chemical composition and a thickness t (mm) of the steel base material regulated to obtain a value, C/0.2+Si/5.0+Mn/1.3+Cr/1.0+Mo/1.2+0.4t?0.7(Cr+Mo)1/2, of 2.9 or less. The high-strength plated steel plate is excellent in corrosion resistance of the welded portion, resistance to liquid metal embrittlement cracking, and bending workability.